HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $293,605 | +11.5% | 7,686 | +5.3% | 0.02% | +15.4% |
| Q2 2023 | $263,347 | -4.2% | 7,301 | +1.5% | 0.01% | -7.1% |
| Q1 2023 | $274,777 | -41.2% | 7,195 | -12.3% | 0.01% | -33.3% |
| Q4 2022 | $467,035 | +44.4% | 8,208 | +0.4% | 0.02% | +31.2% |
| Q3 2022 | $323,358 | -10.1% | 8,178 | 0.0% | 0.02% | 0.0% |
| Q2 2022 | $359,832 | +3.8% | 8,178 | -5.9% | 0.02% | +33.3% |
| Q1 2022 | $346,757 | -85.1% | 8,695 | -84.9% | 0.01% | -62.5% |
| Q4 2021 | $2,321,685 | -5.5% | 57,739 | -4.4% | 0.03% | -11.1% |
| Q3 2021 | $2,457,804 | -11.0% | 60,418 | -0.6% | 0.04% | -7.7% |
| Q2 2021 | $2,761,291 | +17.4% | 60,808 | +7.7% | 0.04% | +11.4% |
| Q1 2021 | $2,353,025 | -5.4% | 56,441 | -3.1% | 0.04% | -5.4% |
| Q4 2020 | $2,487,815 | +137.0% | 58,249 | +45.8% | 0.04% | +105.6% |
| Q3 2020 | $1,049,912 | -7.4% | 39,951 | -5.5% | 0.02% | -10.0% |
| Q2 2020 | $1,133,902 | +55.6% | 42,294 | +4.4% | 0.02% | +33.3% |
| Q1 2020 | $728,865 | -9.7% | 40,515 | -11.0% | 0.02% | +15.4% |
| Q4 2019 | $807,353 | +11.5% | 45,536 | -2.4% | 0.01% | +8.3% |
| Q3 2019 | $723,790 | +0.5% | 46,666 | +11.3% | 0.01% | 0.0% |
| Q2 2019 | $720,031 | +10.1% | 41,911 | +3.1% | 0.01% | 0.0% |
| Q1 2019 | $654,175 | +10.0% | 40,632 | 0.0% | 0.01% | 0.0% |
| Q4 2018 | $594,446 | -19.5% | 40,632 | 0.0% | 0.01% | -7.7% |
| Q3 2018 | $738,283 | -99.9% | 40,632 | 0.0% | 0.01% | +18.2% |
| Q2 2018 | $685,462,000 | -8.7% | 40,632 | +6.0% | 0.01% | 0.0% |
| Q1 2018 | $751,159,000 | +98477.3% | 38,344 | +2.0% | 0.01% | +10.0% |
| Q4 2017 | $762,000 | -44.9% | 37,596 | -52.8% | 0.01% | +11.1% |
| Q3 2017 | $1,383,000 | +44.8% | 79,604 | +6.9% | 0.01% | +28.6% |
| Q2 2017 | $955,000 | -1.0% | 74,477 | 0.0% | 0.01% | 0.0% |
| Q1 2017 | $965,000 | +29.2% | 74,477 | -1.5% | 0.01% | +40.0% |
| Q4 2016 | $747,000 | -19.5% | 75,639 | -1.5% | 0.01% | -28.6% |
| Q3 2016 | $928,000 | +40.4% | 76,812 | +0.3% | 0.01% | +40.0% |
| Q2 2016 | $661,000 | -11.4% | 76,589 | -2.8% | 0.01% | -16.7% |
| Q1 2016 | $746,000 | -42.2% | 78,814 | +5.8% | 0.01% | -40.0% |
| Q4 2015 | $1,291,000 | +26.1% | 74,505 | -2.3% | 0.01% | +42.9% |
| Q3 2015 | $1,024,000 | -40.5% | 76,263 | 0.0% | 0.01% | -41.7% |
| Q2 2015 | $1,722,000 | +49.9% | 76,263 | -5.2% | 0.01% | +50.0% |
| Q1 2015 | $1,149,000 | +54.9% | 80,462 | +4.7% | 0.01% | +60.0% |
| Q4 2014 | $742,000 | +9.3% | 76,853 | +2.9% | 0.01% | 0.0% |
| Q3 2014 | $679,000 | -8.0% | 74,658 | 0.0% | 0.01% | 0.0% |
| Q2 2014 | $738,000 | -22.2% | 74,658 | 0.0% | 0.01% | -28.6% |
| Q1 2014 | $948,000 | -14.9% | 74,658 | +0.5% | 0.01% | -12.5% |
| Q4 2013 | $1,114,000 | +35.9% | 74,293 | 0.0% | 0.01% | +33.3% |
| Q3 2013 | $820,000 | +40.9% | 74,293 | +1.4% | 0.01% | +20.0% |
| Q2 2013 | $582,000 | – | 73,297 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |